Skip to main content
TipRanks
Go Ultimate75% OFF

BioMark Diagnostics (20B) AI Stock Analysis

5 Followers
DE:20B

BioMark Diagnostics

(Frankfurt:20B)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Early-detection diagnostics focusA focused blood-based diagnostics platform gives BioMark a defined development direction in early detection, an area where clinical validation could support future adoption. Its emphasis on metabolic biomarkers may also allow the company to build specialized expertise around targeted disease applications.
Negative Factors
Sharp revenue contractionThe steep decline in revenue indicates that BioMark has not yet established a stable or expanding commercial base. Sustained contraction reduces operating leverage, limits funding available for diagnostic development, and makes future margin improvement more difficult while the company remains small.

BioMark Diagnostics (20B) vs. iShares MSCI Germany ETF (EWG)

-25%0%25%50%75%100%125%DE:20B+22.00%EWG+7.62%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 44.72M
Dividend Yield
―
Average Volume (3M)
1,500
Price to Earnings (P/E)
-31.1
Beta (1Y)
0.14
Revenue Growth
-83.10%
EPS Growth
28.21%
Country
Germany
Employees
9
Sector
Healthcare
Sector Strength
51
Industry
Medical - Diagnostics & Research

BioMark Diagnostics Business Overview & Revenue Model

Company Description

BioMark Diagnostics Inc. is an oncology specialist, developing advanced diagnostic tools for cancer to enable early detection, continuous patient monitoring, and the assessment of initial treatment efficacy. The firm holds a research partnership with...

BioMark Diagnostics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

DE:20B against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:EDTTSE:EDT41NeutralCAD 306.00M-796.150.50%―-19.82%99.11%
TSE:SONATSE:SONA40UnderperformCAD 31.31M-11.91448.05%――24.65%
TSE:TELOTSE:TELO40UnderperformCAD 4.51M-1.96295.03%――25.57%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%DE:20BTSE:EDTTSE:TELOTSE:SZLS.HTSE:ZYUSTSE:SONADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:20B and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:20BBioMark Diagnostics0.240.0422.00%
TSE:EDTSpectral Medical (Edtxf)1.03-0.30-22.18%
TSE:TELOTelo Genomics0.04-0.01-25.00%
TSE:SZLS.HStagezero Life Sciences0.040.000.00%
TSE:ZYUSZyus Life Sciences Corporation0.39-0.30-44.20%
TSE:SONASona Nanotech, Inc0.26-0.29-52.78%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.